Neoadjuvant chemotherapy associated with isotoxic high‐dose stereotactic body radiotherapy does not increase postoperative complications after pancreaticoduodenectomy for nonmetastatic pancreatic cancer

Abstract

AbstractBackground and ObjectivesThe role of radiotherapy in the therapeutic sequence of nonmetastatic pancreatic cancer (PC) is controversial, including isotoxic high‐dose stereotactic body radiotherapy (iHD‐SBRT). This study aimed to compare postoperative outcome of patients with nonmetastatic PC undergoing neoadjuvant treatment (NAT) including iHD‐SBRT versus upfront pancreaticoduodenectomy (PD).MethodsAll patients undergoing PD for PC from 2017 to 2021 were retrospectively analyzed, identifying patients receiving NAT with iHD‐SBRT. Toxicity of treatments and postoperative outcome were assessed and analyzed in a propensity score‐matched population.ResultsEighty‐nine patients underwent upfront surgery (surgery group) and 22 after NAT and iHD‐SBRT (SBRT group). No major side effects SBRT‐related were identified preoperatively. Postoperative morbidity was similar between groups. There was no postoperative death in SBRT group, and six in surgery group (p = 0.597). No difference was observed in the rates of complications related to pancreatic surgery. The postoperative hospital stay was shorter in SBRT versus surgery groups (p = 0.016). After propensity score matching, no significant difference in the postoperative morbidity was observed between groups.ConclusionsIncorporation of iHD‐SBRT in the NAT sequence before PD for PC did not increase postoperative morbidity compared with upfront surgery. These results confirm the feasibility and safety of iHD‐SBRT for the upcoming STEREOPAC trial.